Affordable Access

Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S).

Authors
Type
Published Article
Journal
The Lancet
1474-547X
Publisher
Elsevier
Publication Date
Volume
364
Issue
9436
Pages
771–777
Identifiers
PMID: 15337403
Source
Medline
License
Unknown

Abstract

Simvastatin treatment for 5 years in a placebo-controlled trial, followed by open-label statin therapy, was associated with survival benefit over 10 years of follow-up compared with open-label statin therapy for the past 5 years only. No difference was noted in mortality from and incidence of cancer between the original simvastatin group and placebo group.

Statistics

Seen <100 times